Dusquetide - Soligenix

Drug Profile

Dusquetide - Soligenix

Alternative Names: Dusquetide; IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer Soligenix; The Childrens Hospital of Philadelphia; University of British Columbia
  • Class Anti-inflammatories; Antibacterials; Peptides; Proteins
  • Mechanism of Action Immunomodulators; SQSTM1-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stomatitis
  • Preclinical Acute radiation syndrome; Lymphoproliferative disorders; Melioidosis
  • No development reported Bacterial infections

Most Recent Events

  • 02 Jan 2018 Soligenix has patent protection for dusquetide in USA
  • 20 Sep 2017 Soligenix receives SBIR grant from National Institute of Dental and Craniofacial Research for dusquetide development in Stomatitis (Chemoradiation therapy-induced)
  • 27 Jul 2017 Phase-III clinical trials in Stomatitis (Chemotherapy-induced) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top